Elanco Launches Osurnia - A Revolution In Otitis Externa Treatment
9 years ago 
4978 views
Elanco Animal Health has launched Osurnia, an easy to use revolutionary treatment which will drive compliance when treating canine otitis externa infections.
Compliance with daily ear drops has been shown to be poor, with up to 80% of owners administering the incorrect dose to their pet. The most common reason for a lack of compliance is the difficultly in applying or the challenge in applying the drops1. Osurnia has the potential to significantly improve compliance in treating otitis externa. This is due to its convenient, two-dose administration schedule a week apart, which will enable veterinary surgeons to take control of canine otitis externa treatment. With other medications, owners must treat their dogs with five to 28 doses of medication throughout the course of treatment2.
Osurnia is a first line treatment that can be prescribed with confidence. It contains a unique gel formulation of three active ingredients. These include the antibiotic florfenicol, which is new to companion animal treatment in the UK, terbinafine, which inhibits the growth of yeast as demonstrated for Malassezia spp., and the glucocorticosteroid, betamethasone acetate, to help relieve discomfort.
Moreover, the innovative gel formulation is a unique treatment for otitis externa as the sustained release gel provides optimal distribution of the treatment throughout the ear canal with less mess. Osurnia is easy to use and is administered in a pre-measured, single-dose tube ensuring the right dose every time. It has a flexible, soft tip that is gentle on a dog’s ears making treatment with Osurnia a comfortable experience for the dog. The gel formulation squeezes out of the tube and spreads through the ear, adhering inside the ear canal for long-lasting action. It is the same dose for any dog, regardless of size and weight.
“Otitis externa is a common challenge for both vets and clients, with ear infections among the ten most frequent reasons for dogs to be presented with vets, affecting up to 20% of dogs3,” comments Alice Laurens, DVM MRCVS, dermatology marketing manager at Elanco Animal Health. “Osurnia is an innovative, effective treatment that is administered in just two doses ensuring it is much more convenient for pet owners thereby increasing the likelihood that they will complete the entire treatment schedule leading to more comfortable dogs and peace of mind for owners.”
Elanco has produced a client leaflet on treating otitis externa with Osurnia. For further information, or to order client leaflets, please contact your local Elanco Animal Health Territory Manager or email [email protected].
References
1 Intern J Appl Res Vet Med, Vol 9, No2, 2011
2 SPCs of other otitis externa treatments
3 Angus J C: Otic cytology in health and disease. Vet Clin. Small Animal 2004, 34, 411-424
More from Elanco
- ACT Against Lungworm for National Dog Day on 26th August!
- New Elanco survey data for national pet month
- New research reveals over a third of dogs with Angiostrongylus vasorum could be symptomless
- Chance to win with Elanco
- Elanco completes parasiticide portfolio expansion with launch of new CredelioTM Plus, offering vets a parasite treatment for every lifestyle